Stocks in Focus. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...

Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...

Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...